Currently, the only treatment for non-alcoholic steatohepatitis (NASH) cirrhosis is a liver transplant. We hope to change that.
The galectin-3 protein is directly involved in many inflammatory, fibrotic, and malignant diseases.
Inhibiting galectin-3 may allow the body’s own immune system to target and destroy cancer cells.
NASH cirrhosis is rapidly becoming the number one reason for liver transplants.
Do you qualify for the NAVIGATE Study?
Galectin Therapeutics is working to improve the lives of patients with NASH cirrhosis, fibrosis, and cancer. Learn more about our NAVIGATE Phase 2b/3 study in NASH cirrhosis.
Galectin Therapeutics develops novel therapies to improve the lives of patients with chronic liver disease and cancer.
Galectin's lead drug, belapectin (GR‑MD‑02), is a carbohydrate-based drug that inhibits the galectin‑3 protein, involved in many inflammatory, fibrotic, and malignant diseases.
The lead development program is in non‑alcoholic steatohepatitis (NASH) cirrhosis, a serious, life‑threatening disease with no current cure.
Corporate Overview View Now
Receive Galectin Therapeutics Inc. financial information by email.
Sign Up
